Role of CD5L and SRD5A2 as Prognostic Biomarkers for Hepatocellular Carcinoma

Luo, Yanwei; Huang, Xiaopeng; Zhan, Jun; Zhang, Shuai

doi:10.2147/ijgm.s337769

Cited by 5 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD5L presented with abnormal mRNA and protein levels in HCC and it was found to be an independent prognostic factor for HCC patients. [63,64] DAB2 promotes epithelial-mesenchymal transition and invasion of tumor cells at advanced tumor stages, and it acts as a risk factor in HCC, [65] which is consistent with our findings. High expression of IMPDH1 is associated with poor prognosis of HCC patients and may serve as a potential target for immunotherapy.…”

Section: Discussionsupporting

confidence: 91%

Prognostic significance of LRRC1 in hepatocellular carcinoma and construction of relevant prognostic model

Cai¹,

Wu²,

Shen

et al. 2023

Medicine

View full text Add to dashboard Cite

This study aimed to elucidate the prognostic value of the leucine rich repeat containing 1 (LRRC1) gene in hepatocellular carcinoma (HCC) and to determine the effects of high and low LRRC1 expression on mutation and immune cell infiltration. We downloaded HCC mRNA-seq expression and clinical data from University of California Santa Cruz Xena. The expression of LRRC1 was compared between HCC tumor and normal samples. Tumor samples were divided according to high and low LRRC1 expression. Differentially expressed genes between the 2 groups were identified, and function, mutation, and immune cell infiltration were analyzed. Genes associated with immune cells were identified using weighted gene co-expression network analysis, and transcription factors of these genes were predicted. Moreover, a prognostic model was developed and its performance was evaluated. The expression of LRRC1 was upregulated in HCC tissues, and this indicated a poor prognosis for patients with HCC. Differentially expressed genes between high and low LRRC1 expression were significantly enriched in pathways associated with cancer, amino acid metabolism, carbohydrate metabolism, and the immune system. We identified 15 differentially infiltrated immune cells between tumors with high and low LRRC1 expression and 14 of them correlated with LRRC1 gene expression. Weighted gene co-expression network analysis identified 83 immune cell-related genes, 27 of which had prognostic value. Cyclic AMP-response element binding protein regulated annexin A5, matrix metallopeptidase 9, and LRRC1 in the transcription factor regulatory network. Finally, a prognostic model composed of 7 genes were generated, which could accurately predict the prognosis of HCC patients. The LRRC1 gene might serve as a potential immune-associated prognostic biomarker for HCC.

show abstract

Section: Discussionsupporting

confidence: 91%

Prognostic significance of LRRC1 in hepatocellular carcinoma and construction of relevant prognostic model

Cai¹,

Wu²,

Shen

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…Moreover, the LIHC patients with high-CD5L mRNA levels showed a favorable prognosis. Consistently, Luo et al 's [ 21 ] study also showed that CD5L can be an independent favorable prognostic factor for LIHC patients. Interestingly, our analysis further showed that there was no significant prognostic value of CD5L mRNA expression in LIHC patients with hepatitis virus infection.…”

Section: Discussionsupporting

confidence: 60%

Exogenous CD5L inhibits liver hepatocellular carcinoma cell proliferation and role of CD5L as prognostic marker

Gao

Wu²,

Yang

et al. 2023

Chinese Medical Journal

View full text Add to dashboard Cite

Background: CD5L (CD5 molecular-like) plays an important role in lipid metabolism and immune regulation. This study aimed to investigate the roles of CD5L on liver hepatocellular carcinoma (LIHC). Methods: We analyzed the CD5L mRNA expression and its potential prognostic value based on The Cancer Genome Atlas and Gene Expression Omnibus databases. Immunohistochemical analysis was used to investigate the CD5L levels in LIHC tissues. Serum CD5L levels in LIHC were detected by enzyme-linked immunosorbent assay. Cell Counting Kit-8 (CCK-8) assay was used to investigate the effect of CD5L treatment on HepG2 and QSG-7701 cell proliferation. CD5L expression correlated genes were exhumed based on the LinkedOmics. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses for CD5L associated genes were performed. The correlation between CD5L and tumor immune infiltration was analyzed by using Tumor Immune Estimation Resource (TIMER) 2.0. Results: CD5L mRNA and protein levels were significantly decreased in LIHC tumor tissue compared with non-tumor control tissues. Moreover, serum CD5L levels were significantly lower in LIHC patients than that in healthy subjects. Gene Expression Profiling Interactive Analysis 2 and Kaplan-Meier plotter analysis showed that a high-CD5L expression was correlated with favorable overall survival in LIHC patients, except the LIHC patients with hepatitis virus. CCK-8 results showed that CD5L treatment significantly decreased HepG2 cell proliferation in a concentration-dependent manner, and CD5L treatment had no effect on the proliferation of non-tumor hepatocyte line QSG-7701. CD5L associated genes were enriched in the immune response biological process, and CD5L expression levels were positively correlated with the immune infiltrates of CD8 + T cell and M1 macrophage cells but negatively correlated with CD4 + T cells and M0 macrophage cell infiltration. Conclusions: Exogenous CD5L inhibits cell proliferation of hepatocellular carcinoma. CD5L may act as a role of prognostic marker.

show abstract

Serum CD5L as potential biomarker of thyroid hormone status during pregnancy

Asaad,

Chillon,

Filipowicz

et al. 2024

BioFactors

View full text Add to dashboard Cite

The thyroid hormone (TH) status is routinely assessed by thyrotropin (TSH) and thyroxine (T4). Both biomarkers are mainly regulated by TH receptor beta, whereas many peripheral organs employ the alpha receptor. Serum cluster of differentiation 5‐like molecule (CD5L) is a liver‐derived protein under control of both TH receptor isoforms. However, clinical data on its relation to TH status are sparse. An additional biomarker of TH status is needed in particular during pregnancy, where the routine biomarkers become dynamically disturbed. This study aimed to determine possible covariates regulating serum CD5L and to test its potential suitability as additional TH biomarker during pregnancy. A sandwich ELISA for serum CD5L was established using newly raised antibodies. Circadian effects and the impact of liver disease on serum CD5L concentrations were assessed. Serum samples from pregnant women with well‐characterized TH and trace element status were analyzed, and CD5L concentrations were correlated with other indicators of TH status including TSH, fT4, fT3, copper, and selenium concentrations. The new quantitative assay for CD5L showed high accuracy. Serum CD5L was stable in dilution and refreezing experiments and did not show strong circadian variance or dependency on liver disease. In serum of pregnant women, CD5L correlated positively to fT3, but not to fT4 or TSH. Significant positive correlations of CD5L were observed with serum levels of the TH‐responsive trace elements selenium and copper. The data support the potential suitability of serum CD5L as an additional marker of TH status, with potential value for pregnancy and thyroid disease.

show abstract

Role of CD5L and SRD5A2 as Prognostic Biomarkers for Hepatocellular Carcinoma

Cited by 5 publications

References 30 publications

Prognostic significance of LRRC1 in hepatocellular carcinoma and construction of relevant prognostic model

Prognostic significance of LRRC1 in hepatocellular carcinoma and construction of relevant prognostic model

Exogenous CD5L inhibits liver hepatocellular carcinoma cell proliferation and role of CD5L as prognostic marker

Serum CD5L as potential biomarker of thyroid hormone status during pregnancy

Contact Info

Product

Resources

About